Global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market - 2023-2030

Overview

Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder, which is characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. It can occur due to various factors, including pneumonia, abnormalities of cilia, and immune deficiencies. It most frequently affects the elderly. Patients suffering from NCFB generally experience increased morbidity and worse quality of life.

Moreover, NCFB cannot be cured but can be managed with treatment. The treatment includes airway clearance by using various types of airway clearance devices such as vest airway clearance system and positive expiratory pressure valve is most commonly used, pneumococcal and influenza vaccination, macrolides are used to reduce airway mucus secretion and viscosity, antibiotics are used to lower bacterial burden and reduce most markers of inflammation, physiotherapy, pulmonary rehabilitation and bronchodilators are also used to manage the severity of the condition.

Market Dynamics: Drivers

Increasing regulatory approvals and novel drug launches

The increasing regulatory approvals and novel drug launches are expected to drive the market over the forecast period. Regulatory approvals such as FDA approvals pave the way for new drugs and therapies to enter the market with safety. This expansion of treatment options provides patients with more choices, allowing for personalized treatment plans based on individual patient needs and characteristics. These regulatory approvals increase the trust in patients about the usage of novel drugs.

For instance, on June 8, 2020, Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, cleared that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFB) for reducing exacerbations.

Moreover, many clinical trials are going on for the development of novel drugs that show better results in the management of the NCFB. Novel drugs often undergo testing by performing clinical trials to demonstrate their efficacy and safety. For instance, in November 2022, Renovion, Inc. cleared that the first patient had enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFB).

Additionally, on February 22, 2022, Armata Pharmaceuticals, Inc., released that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application to initiate a phase 2 clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (NCFB).

Further, the increasing prevalence of non-cystic fibrosis bronchiectasis, increasing clinical trials, increasing adoption of nebulizers, technological advancements in physiotherapy and airway clearance devices, increasing awareness and advancements in the development of novel treatment options are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the treatment drugs, the high cost of the treatment, side effects associated with physiotherapy and lack of better and appropriate treatment options, availability of alternative treatment options are expected to hamper the market.

Segment Analysis

The global non-cystic fibrosis bronchiectasis (NCFB) treatment market is segmented based on treatment type, route of administration, sales channel and region.

The airway clearance segment accounted for approximately 46.2% of the non-cystic fibrosis bronchiectasis (NCFB) treatment market share

The airway clearance segment is expected to hold the largest market share over the forecast period. There is no cure for non-cystic fibrosis bronchiectasis, but airway clearance treatment is most commonly used for the management of the disease and its severity. Patients are often trained to perform airway clearance techniques at home. This may involve the use of devices or manual techniques that can be administered independently or with the help of a caregiver.

Moreover, due to the rising prevalence, the demand for airway clearance is continuously increasing. For instance, according to the National Institute of Health (NIH), the incidence of non-cystic fibrosis bronchiectasis is 2-5 patients per 1,000 population. It is more common in the elderly and older, frailer patients tend to have a more severe and symptomatic disease. In one study performed by NIH, over 1,200 patients with bronchiectasis, 50% were over 65 years old and 19.1% were over 75 years.

Further, deep breathing exercises and controlled breathing techniques are often incorporated into airway clearance routines. These exercises can help improve lung capacity and promote the clearance of mucus. Airway clearance devices such as the vest airway clearance system and positive airway pressure devices are most commonly used. In addition, their wide adoption also increases the demand for airway clearance devices.

Geographical Analysis

North America accounted for approximately 39.6% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing FDA approvals. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. The presence of major players actively performing in research activities and clinical trials, which leads to the launch of novel therapeutics.

Furthermore, increasing research activities in the region leads to advanced treatment options and the FDA approvals for this novel therapeutics in the region are continuously increasing. For instance, on April 21, 2022, the Food and Drug Administration (FDA) granted Breakthrough Therapy designation to colistimethate sodium powder for nebulization solution (CMS I-neb) for the reduction in the incidence of pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa.

Competitive Landscape

The major global players in the non-cystic fibrosis bronchiectasis (NCFB) treatment market include: Insmed Incorporated, Johari Digital Healthcare Ltd., HMS Medical Systems, Merck & Co., Inc., Baxter International Inc., Ralington Pharma LLP, AdvaCare Pharma, Pfizer Inc., Life Care Systems and VIVAN Life Sciences, among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global non-cystic fibrosis bronchiectasis (NCFB) treatment market. The pandemic led to disruptions in ongoing clinical trials and delays in the initiation of new trials. This impacted the development and approval of novel treatments for NCFB. The pandemic accelerated the adoption of telemedicine as a means of providing healthcare services remotely. This shift could influence the management of NCFB, with virtual consultations for routine follow-ups and prescription renewals. The pandemic also disrupted the supply chain of these treatment drugs and devices globally.

Market Segmentation

By Treatment Type

• Physiotherapy
• Vaccination
  • Pneumococcal Vaccination
  • Influenza Vaccination
• Airway Clearance
• Pulmonary Rehabilitation
• Antibiotics
  • Gentamicin
  • Ceftazidime
  • Colistin
  • Ciprofloxacin
  • Others
• Macrolides
  • Erythromycin
  • Clarithromycin
  • Roxithromycin
  • Azithromycin
  • Others
• Oral Steroids
• Bronchodilators
  • SABA
  • LABA
• Others

By Route Of Administration

• Oral
• Nasal
• Intravenous
• Others

By Sales Channel

• Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End-User
  • Hospitals
  • Specialty Clinics
  • Rehabilitation Centers
  • Physiotherapy Centers
  • Vaccination Centers
  • Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?

• To visualize the global non-cystic fibrosis bronchiectasis (NCFB) treatment market segmentation based on treatment type, route of administration, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of non-cystic fibrosis bronchiectasis (NCFB) treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global non-cystic fibrosis bronchiectasis (NCFB) treatment market report would provide approximately 61 tables, 63 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies